• Thumbnail for Bruton's tyrosine kinase
    Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans...
    22 KB (2,389 words) - 06:43, 22 April 2024
  • Thumbnail for Ogden Bruton
    name: "Bruton-type agammaglobulinemia". The gene associated with this defect is also named after him: Btk, abbreviation for Bruton's tyrosine kinase. He...
    8 KB (994 words) - 15:07, 18 April 2024
  • Thumbnail for Phosphoinositide 3-kinase
    been identified that are regulated by PtdIns(3,4,5)P3, including Bruton's tyrosine kinase (BTK), General Receptor for Phosphoinositides-1 (GRP1), and the...
    32 KB (3,463 words) - 17:34, 20 November 2023
  • Thumbnail for X-linked agammaglobulinemia
    develop serious and even fatal infections. A mutation occurs at the Bruton's tyrosine kinase (Btk) gene that leads to a severe block in B cell development (at...
    15 KB (1,814 words) - 16:26, 20 February 2023
  • Thumbnail for Tyrosine-protein kinase SYK
    Tyrosine-protein kinase SYK, also known as spleen tyrosine kinase, is an enzyme which in humans is encoded by the SYK gene. SYK, along with ZAP70, is...
    18 KB (2,083 words) - 06:18, 25 December 2023
  • Thumbnail for Nemtabrutinib
    Nemtabrutinib (category Tyrosine kinase inhibitors)
    formerly ARQ 531) is a small molecule drug that works as a reversible Bruton's tyrosine kinase (BTK) inhibitor; unlike other BTK inhibitors it also works against...
    7 KB (501 words) - 19:50, 24 April 2024
  • ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes...
    12 KB (877 words) - 15:36, 25 January 2024
  • including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. In addition to clinical research, BeiGene's early business...
    25 KB (2,299 words) - 17:57, 21 May 2024
  • Thumbnail for Zanubrutinib
    Zanubrutinib (category Kinase inhibitors)
    chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth. It was approved for medical...
    23 KB (1,765 words) - 02:36, 28 April 2024
  • Thumbnail for Mantle cell lymphoma
    standard of care, but numerous clinical trials are ongoing. Two Bruton tyrosine kinase inhibitors (BTKi), one In November 2013, ibrutinib (brand name Imbruvica...
    41 KB (4,549 words) - 08:59, 25 January 2024